Cormedix (Cormedix) Interest Expense : $-0.04 Mil (TTM As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Cormedix Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cormedix's interest expense for the three months ended in Mar. 2024 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.04 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cormedix's Operating Income for the three months ended in Mar. 2024 was $ -16.70 Mil. Cormedix's Interest Expense for the three months ended in Mar. 2024 was $ -0.01 Mil. Cormedix did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cormedix Interest Expense Historical Data

The historical data trend for Cormedix's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cormedix Interest Expense Chart

Cormedix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.79

-0.03

-0.02

-0.03

Cormedix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.01	-0.01	-0.01	-0.01

Cormedix Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.

Cormedix (NAS:CRMD) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cormedix's Interest Expense for the three months ended in Mar. 2024 was $-0.01 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-16.70 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.48 Mil.

Cormedix's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Cormedix did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Cormedix (Cormedix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (NAS:CRMD) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

19KA:Germany

Address

300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922

Website

https://www.cormedix.com

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.

Executives

Alan W Dunton	director	VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Erin Mistry	officer: Chief Commercial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Joseph Todisco	director, officer: Chief Executive Officer	400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Myron Kaplan	director	C/O KLEINBERG, KAPLAN, WOLFF & COHEN, PC, 551 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10176
Paulo F Costa	director	MACROGENICS, INC., ONE CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Robert A Stewart	director	360 MT. KEMBLE AVENUE, MORRISTOWN NJ 07960
Janet Dillione	director	ONE WAYSIDE ROAD, BURLINGTON MA 01803
Matthew T David	officer: EVP, Chief Financial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Elizabeth Masson	officer: EVP, Head of Clinical Ops.	400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07922
Thomas Nusbickel	officer: EVP, Chief Commercial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Gregory Scott Duncan	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Steven W Lefkowitz	director	SIX HARRISON STREET, NEW YORK NY 10013
Mehmood Khan	director	700 ANDERSON HILL ROAD, PURCHASE NY 10577
Armstrong Jr. John L.	officer: Exec VP of Tech Operations	C/O CORMEDIX INC., 1430 U.S. HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Khoso Baluch	director, officer: Chief Executive Officer	1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921